Response rate as an approval end point in oncology: Back to the future

JAMA Oncology

Volumn 2, Issue 6, 2016, Pages 780-781

  Blumenthal, Gideon M ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOASSAY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; NEOPLASMS; ONCOLOGY; PATHOLOGY; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; ENDPOINT DETERMINATION; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85010410288     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.6352     Document Type: Note

References (7)

1. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13(suppl 2):19-21.
2. Axelson M, Liu K, Jiang X, et al. US Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19(9):2289-2293.
3. Kurzrock R, Stewart DJ. Equipoise abandoned? randomization and clinical trials. Ann Oncol.2013;24(10):2471-2474.
4. Simon R, Blumenthal GM, Rothenberg ML, et al. The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther. 2015;97(5):502-507.
5. Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH. Response rate as a regulatory end point in single-arm studies of advanced solid tumors [published online February 18, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2015.6315.
6. Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015;33(9):1008-1014.
7. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801-1811.